JPRN-jRCT2011260019 Izalontamab Brengitecan Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCT2011260019—IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCT2011260019 is a hot trial to watch

Squamous non-small cell lung cancer is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCT2011260019 is notable because it evaluates Izalontamab Brengitecan in a Phase 2/3 design while PFS by RECIST v1.1 per BICR serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of 500 participants across Taiwan Province, Italy, Greece, South Korea, Germany, Argentina, Chile, Canada, Colombia, Japan, France, India, Netherlands, Belgium, Switzerland, Spain, Mexico, United Kingdom, Thailand, Singapore, United States, Poland, China, Romania, Norway shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: PFS by RECIST v1.1 per BICR
• Primary: RECIST v1.1 に基づくBICR によるPFS
• Secondary: 全生存期間（OS）、RECIST v1.1 に基づく治験責任（分担）医師判定によるPFS、RECIST v1.1 に基づくBICR によるOR・DCR・DOR・TTR
• Secondary: OS, PFS by RECIST v1.1 per investigator assessment, OR/DCR/DOR/TTR by RECIST v1.1per BICR

Benchmark readouts in the surrounding field

• A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (Phase 2): Number of Participants With Surgical Delays = 0 Participants ; Number of Participants With Surgical Delays = 4 Participants
• First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307 (Phase 3): mPFS = 9.5 month ( 7.4 - 10.1); mPFS = 7.7 month ( 6.7 - 9.9)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China (Phase 3): TRAE(grade 3 or higher) = 156.0 Pts ; TRAE(grade 3 or higher) = 184.0 Pts

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Izalontamab Brengitecan (Approved; EGFR x HER3 x Top I)

Company & Deal Intelligence context: Bristol Myers Squibb Co. — United States — http://www.bms.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

JPRN-jRCT2011260019 is a focused lens on Squamous non-small cell lung cancer development. Its value will be determined by whether Izalontamab Brengitecan can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.